| Literature DB >> 35967868 |
Eduardo Rodríguez-Noriega1, Elvira Garza-González2, Paola Bocanegra-Ibarias2, Beatriz Alejandra Paz-Velarde3, Sergio Esparza-Ahumada1,3, Esteban González-Díaz1,3, Héctor R Pérez-Gómez1, Rodrigo Escobedo-Sánchez3, Gerardo León-Garnica1,3, Rayo Morfín-Otero1.
Abstract
Introduction: Infections caused by antimicrobial-resistant bacteria are a significant cause of death worldwide, and carbapenemase-producing bacteria are the principal agents. New Delhi metallo-beta-lactamase-1 producing Klebsiella pneumoniae (KP-NDM-1) is an extensively drug-resistant bacterium that has been previously reported in Mexico. Our aim was to conduct a case-control study to describe the risk factors associated with nosocomial infections caused by K. pneumoniae producing NDM-1 in a tertiary-care hospital in Mexico.Entities:
Keywords: Klebsiella pneumoniae; NDM-1; bacterial resistance; carbapenemases; healthcare-associated infections; metallo-beta-lactamases; resistance mechanisms
Mesh:
Substances:
Year: 2022 PMID: 35967868 PMCID: PMC9366880 DOI: 10.3389/fcimb.2022.867347
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Characteristics of cases of patients infected with Klebsiella pneumoniae NDM-1 and controls.
| Variable | Cases | Controls | OR |
|
|---|---|---|---|---|
| Gender, males/females | 86 (61.9)/53 (38.1) | 324 (66.7)/162 (33.3) | 1.233 | 0.171 |
| Age (years) | 41.17 ± 22.74 | 42.04 ± 25.11 | 0.714 | |
| Diabetes mellitus | 34 (24.5) | 111 (22.8) | 1.094 | 0.384 |
| Hypertension | 40 (28.8) | 139 (28.6) | 1.009 | 0.523 |
| Neurological disease | 59 (42.4) | 154 (31.7) | 1.590 | 0.013 |
| Cardiac disease | 33 (23.7) | 80 (16.5) | 1.580 | 0.035 |
| Lung disease | 46 (33.1) | 151 (31.1) | 1.097 | 0.361 |
| Liver disease | 7 (5) | 28 (5.8) | 0.867 | 0.467 |
| Biliary disease | 5 (3.6) | 25 (5.1) | 0.688 | 0.309 |
| Acute renal failure | 54 (38.8) | 75 (15.4) | 3.481 | <0.001* |
| Chronic renal failure | 15 (10.8) | 58 (11.9) | 0.893 | 0.421 |
| Transplant | 5 (3.6) | 8 (1.6) | 2.229 | 0.140 |
| Immunosuppression | 21 (15.1) | 55 (11.3) | 1.395 | 0.145 |
| Alcoholism | 24 (17.3) | 125 (25.7) | 0.603 | 0.023 |
| Cancer | 6 (4.3) | 38 (7.8) | 0.532 | 0.105 |
| Previous hospitalization (6 months) | 48 (34.5) | 155 (31.9) | 1.126 | 0.313 |
| Previous surgery (1 month) | 18 (12.9) | 43 (8.8) | 1.533 | 0.103 |
| Glasgow coma scale | 11.46 ± 3.9 | 13.36 ± 3.12 | <0.001* | |
| SOFA | 4.37 ± 4.08 | 2.58 ± 3.02 | <0.001* | |
| APACHE II score | 4.37 ± 4.08 | 2.58 ± 3.02 | <0.001* | |
| Creatinine | 1.34 ± 2.02 | 2.4 ± 9.14 | 0.201 | |
| Alkaline phosphatase | 171.8 ± 138.1 | 123.95 ± 104.4 | <0.001* | |
| Procalcitonin | 10.31 ± 28.14 | 5.61 ± 15.08 | 0.103 | |
| C-reactive protein | 167.34 ± 94.8 | 82.83 ± 91.3 | <0.001* | |
| Days of hospital stay | 43.05 ± 31.3 | 15.58 ± 14.4 | <0.001* | |
| Mortality risk | 26.14 ± 19.39 | 17.97 ± 14.8 | <0.001* | |
| Outcome | 89 (64) | 445 (91.6) | 6.098 | <0.001* |
| Improvement | 50 (36) | 41 (8.4) |
Values are expressed as mean ± SD or n (%).
SOFA, Sequential Organ Failure Assessment score; APACHE, Acute Physiology and Chronic Health Evaluation.
*p-value is less than 0.05.
Previous antibiotics used for patients infected with Klebsiella pneumoniae NDM-1 and controls.
| Variable | Cases | Controls | OR |
|
|---|---|---|---|---|
| Previous antibiotics | 133 (95.7) | 313 (64.4) | 12.252 | <0.001* |
| Meropenem | 94 (67.6) | 53 (10.9) | 17.066 | <0.001* |
| Linezolid | 72 (51.8) | 53 (10.9) | 8.779 | <0.001* |
| Piperacillin/tazobactam | 45 (32.4) | 48 (9.9) | 4.368 | <0.001* |
| Tigecycline | 61 (43.9) | 22 (4.5) | 33.770 | <0.001* |
*p-value is less than 0.05.
Sources of Klebsiella pneumoniae NDM-1 isolates.
| Isolation source | No. of isolates (%) |
|---|---|
| Urine | 41 (29.5) |
| Respiratory sources | 28 (20.1) |
| Blood | 28 (20.1) |
| Wound secretions | 28 (20.1) |
| Intra-abdominal | 6 (4.4) |
| Vascular catheter | 4 (2.9) |
| Cerebrospinal fluid | 4 (2.9) |
Multivariate analysis of risk factors associated with Klebsiella pneumoniae NDM-1 infection.
| Variable | OR | 95% confidence interval |
|
|---|---|---|---|
| Surgery | 1.713 | 1.146–2.560 | 0.009 |
| Intensive care unit stay | 2.334 | 1.564–3.483 | <0.001 |
| Central venous catheter | 5.518 | 3.631–8.385 | <0.001 |
| Mechanical ventilation | 3.459 | 2.341–5.109 | <0.001 |
| Blood transfusion | 2.445 | 1.664–3.592 | <0.001 |
| Urinary catheter | 5.985 | 3.495–10.249 | <0.001 |
| Previous antibiotics (any) | 12.252 | 5.296–28.346 | <0.001 |
| Previous meropenem | 17.066 | 10.821–26.915 | <0.001 |
| Previous linezolid | 8.779 | 5.664–13.608 | <0.001 |
| Previous piperacillin/tazobactam | 4.368 | 2.747–6.496 | <0.001 |
| Previous tigecycline | 33.770 | 17.019–67.008 | <0.001 |